Table 2.
Individual pharmacokinetic parameters of patients with severe renal impairment (GFRio ≤ 30 ml min−1) or without severe renal impairment
| Severe renal impairment (n = 10) | Without severe renal impairment (n = 38) | |
|---|---|---|
| Nefopam | ||
| Clearance (l h−1) | 13.04 ± 1.45 [8.92–13.50] | 24.61 ± 13.43* [10.44–66.91] |
| Cmax (μg l−1) | 156.2 ± 122.4 [52.9–477.4] | 148.2 ± 131.8 [19.2–512.8] |
| RCmax (μg l−1) h−1) | 315.10 ± 264.40 [103.90–1037.00] | 290.70 ± 268.30 [37.73–1037.00] |
| AUC0→∞ (μg l−1 h) | 1617.0 ± 367.3 [1087.0–2585.0] | 1184 ± 540.6* [382.5–3620] |
| Desmethyl-nefopam | ||
| Clearance (l h−1) | 16.82 ± 8.82 [2.92–28.93] | 17.92 ± 14.88 [3.34–90.46] |
| Cmax (μg l−1) | 7.0 ± 6.1 [1.2–23.0] | 4.9 ± 3.2 [1.3–12.6] |
| RCmax (μg l−1) h−1) | 0.67 ± 0.83 [0.05–2.95] | 1.15 ± 1.16 [0.09–4.87] |
| AUC0→∞ (μg l−1 h) | 141.7 ± 127.0 [25.8–470.5] | 95.1 ± 67.1 [12.0–281.5] |
Abbreviation is as follows: AUC0→∞, Area Under Curve of time course of plasma concentration; Cmax, plasma maximum concentration; GFRio, glomerular filtration rate estimated by iohexol administration; RCmax, rate of increase of plasma concentration.
*
P < 0.05, compared with severe renal impairment (Mann–Whitney U test). Data are means ± SD [range].